CERC's drug is anti-TNF only. Which TNF is an important one in COVID and one that leronlimab downregulates. They certainly chose the right inclusion/exclusion criteria which fits mild to moderate and endpoint (alive and free of respiratory failure). Anti-TNF only for severe or above would almost certainly not been enough.

Under that criteria for CD10 leronlimab should have blown the numbers out of the water. With CERC-02 just barely meeting statistical significance and 83 patients their EUA filing is a bit premature.